Hangzhou Alltest Biotech Co., Ltd. (SHA:688606)

China · Delayed Price · Currency is CNY

41.31

-0.98 (-2.32%)

Jul 13, 2026, 3:00 PM CST

-38.25% (1Y)

Market Cap	3.20B -37.5%
Revenue (ttm)	892.24M +2.0%
Net Income	178.37M -44.1%
EPS	2.24 -44.4%
Shares Out	77.38M
PE Ratio	18.42
Forward PE	n/a
Dividend	2.00 (4.73%)
Ex-Dividend Date	Jun 1, 2026

Volume	501,719
Open	42.29
Previous Close	42.29
Day's Range	41.30 - 42.78
52-Week Range	39.80 - 78.20
Beta	0.19
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 29, 2026

About Hangzhou Alltest Biotech

Hangzhou Alltest Biotech Co., Ltd. engages in the research, development, production, and sale of in vitro diagnostic reagents in China and internationally. The company offers COVID-19 solutions, such as antigen combo rapid and antigen test range; HUMAN RAPID TESTs, including women’s health, infectious disease, drugs of abuse, tumor markers, cardiac markers, home use, and other rapid tests; LF readers; and veterinary products comprising veterinary chemiluminescence and fluorescence immunoassay, veterinary LF readers, dry biochemistry, and immuno... [Read more]

Industry Medical Instruments & Supplies

Sector Healthcare

Founded 2009

Employees 992

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688606

Full Company Profile

Financial Performance

In 2025, Hangzhou Alltest Biotech's revenue was 905.34 million, an increase of 4.47% compared to the previous year's 866.58 million. Earnings were 220.19 million, a decrease of -27.20%.

Financial Statements